Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179283 · ClinicalTrials.gov registry record · Phase 3
Sertraline vs. Venlafaxine XR
A Phase 3 study of Major Depressive Disorder, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00179283: Completed Phase 3 study of Major Depressive Disorder, sponsored by Vanderbilt University.
NCT00179283 is a Phase 3 study of Major Depressive Disorder that has completed, run by Vanderbilt University. The registered enrollment target is 20 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179283, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline vs. venlafaxine Extended Release in the acute treatment of Major Depression in male and female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated randomized list.
Conditions Studied
Interventions
- DRUG sertraline
- DRUG venlafaxine XR
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-04 |
| Phase | Phase 3 |
What the finished NCT00179283 record still lists
NCT00179283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which sertraline is the first listed.
NCT00179283 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00179283 about?
NCT00179283 is a clinical study titled "Sertraline vs. Venlafaxine XR". This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline vs. venlafaxine Extended Release in the acute treatment of Major Depression in male and female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to receive e...
What is the current status of trial NCT00179283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2002-04. Estimated completion is 2003-04.
What conditions does trial NCT00179283 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00179283?
The interventions under investigation include: sertraline (DRUG), venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT00179283?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179283 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00179283's enrollment target sits among peer trials
20 243rd of 282 higher than 34 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia